[摘要]　目的：研究Bcl-2和整合素α3蛋白在非小细胞肺癌组织中的阳性及其对肿瘤生物学行为和患者预后的影响。

方法：应用免疫组化方法检测269例根治术后非小细胞肺癌组织中Bcl-2和整合素α3蛋白表达水平，SPSS10.0统计软件包进行数据分析。

结果：在269例非小细胞肺癌中，Bcl-2蛋白阳性153例，占56.9％；整合素α3蛋白阳性127例，占47.2％，Bcl-2和整合素α3均阳性94例，占34.9％。Bcl-2蛋白在女性非小细胞肺癌组织内阳性率显著高于男性患者，而且与肿瘤的大小呈负相关。整合素α3蛋白在女性和非鳞癌组织内阳性率显著高于男性和肺鳞癌。COX模型多因素分析显示，Bcl-2蛋白阳性是Ⅱ期非小细胞肺癌独立的预后不良因素（五年生存率39.3% 对该蛋白阴性者为52.1%  P=0.04）；Bcl-2和整合素α3蛋白均阳性是Ⅲa期非小细胞肺癌独立的预后良好因素（五年生存率34.5% 对两蛋白其他结果组合为23.8% ，P=0.02）。

结论：Bcl-2和整合素α3蛋白的阳性影响非小细胞肺癌的生物学行为，检测两种蛋白的阳性情况对患者预后有一定预测价值。

[关键词]　肺肿瘤；非小细胞肺癌；Bcl-2；整合素α3；预后


[Abstract]　Purpose：To study the expressions and its clinical significances of bcl-2 and integrinα3 in human Non-small cell lung cancer（NSCLC）after radical surgical resection.

Methods：Immunohistochemical (IHC) staining of bcl-2 and integrinα3 was performed on paraffin-embedded sections from 269 NSCLC patients who underwent surgery and were followed up for 1.1 to 122.2(median, 48.4) months postoperatively. Differences in survival rates and clinical characteristics were evaluated by SPSS10.0 statistical software packet.

Results：The prevalence of bcl-2, integrinα3 and both these proteins expression in NSCLCs was 56.9%, 47.2% and 34.9%, respectively. Bcl-2 expression was seen more frequently in female NSCLCs and smaller tumors. Integrinα3 was seen more frequently in squamous carcinomas. Cox multivariate analysis showed that bcl-2 expression in stage Ⅱ NSCLC was an independent risk factor (5 years survival rate: 39.3% vs 52.1% P=0.04)，and both bcl-2 and integrin α3 positive in stage Ⅲa NSCLC are independent good factors(5 years survival rate: 34.5% vs 23.8% P=0.04).

Conclusions：Bcl-2 and integrin α3 are indicators of NSCLC biological behavior. Combined analysis of expression of these proteins in tumors may indicate the prognosis of NSCLC.

[Key words]　lung neoplasm;non-small cell lung cancer;bcl-2;integrinα3;prognosis



点击浏览全文